Novavax

NVAX

Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III clinical trial in older adults for its candidate vaccine for seasonal influenza, NanoFlu and a candidate vaccine for prevention of COVID-19.

Novavax has been a target of short sellers for a while. The current short interest of 29.58% is roughly at the average of the last 12 months (29.29%).